Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2023-10-18 00:00:00 ET · period of report 2023-10-16 · accession 0001415889-23-014412 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-18 | 2023-10-16 | TBPH | GRAHAM RICHARD A | SVP, RESEARCH, DEVELOPMENT | S - Sale | $9.03 | -2,482 | 334.3K | -0.7% | -$22.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-10-16 | S | D | 2,482 | $9.03 | 334,321 | D | — | — | (F1) This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. |